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Stephen D. Silberstein, M.D., David W. Dodick, M.D., Marcelo E. Bigal, M.D., Ph.D., Paul P. Yeung, M.D., M.P.H.,
Peter J. Goadsby, M.D., Ph.D., Tricia Blankenbiller, M.A., Melissa Grozinski‑Wolff, B.S., Ronghua Yang, Ph.D.,
Yuju Ma, M.S., and Ernesto Aycardi, M.D.

a bs t r ac t
BACKGROUND

Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene–related
peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic
migraine.
METHODS

In this phase 3 trial, we randomly assigned patients with chronic migraine (defined
as headache of any duration or severity on ≥15 days per month and migraine on
≥8 days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single
dose of 675 mg at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), or matching placebo. Both
fremanezumab and placebo were administered by means of subcutaneous injection. The primary end point was the mean change from baseline in the average
number of headache days (defined as days in which headache pain lasted ≥4 consecutive hours and had a peak severity of at least a moderate level or days in which acute
migraine–specific medication [triptans or ergots] was used to treat a headache of any
severity or duration) per month during the 12 weeks after the first dose.
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RESULTS

Of 1130 patients enrolled, 376 were randomly assigned to fremanezumab quarterly,
379 to fremanezumab monthly, and 375 to placebo. The mean number of baseline
headache days (as defined above) per month was 13.2, 12.8, and 13.3, respectively.
The least-squares mean (±SE) reduction in the average number of headache days
per month was 4.3±0.3 with fremanezumab quarterly, 4.6±0.3 with fremanezumab
monthly, and 2.5±0.3 with placebo (P<0.001 for both comparisons with placebo).
The percentage of patients with a reduction of at least 50% in the average number
of headache days per month was 38% in the fremanezumab-quarterly group, 41% in
the fremanezumab-monthly group, and 18% in the placebo group (P<0.001 for both
comparisons with placebo). Abnormalities of hepatic function occurred in 5 patients
in each fremanezumab group (1%) and 3 patients in the placebo group (<1%).
CONCLUSIONS

Fremanezumab as a preventive treatment for chronic migraine resulted in a lower
frequency of headache than placebo in this 12-week trial. Injection-site reactions
to the drug were common. The long-term durability and safety of fremanezumab
require further study. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number,
NCT02621931.)
n engl j med 377;22
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A Quick Take
is available at
NEJM.org

igraine is a complex neurologic
disorder that is characterized primarily
by recurrent attacks of pulsating headache pain of at least moderate severity.1,2 It has a
global prevalence of 15 to 18% and is a leading
cause of disability worldwide.3 Chronic migraine,
occurring in approximately 2% of the population, has been defined as the occurrence of at
least 15 days with headache per month for at least
3 months.2,4 With daily or near-daily attacks, persons with chronic migraine have functional impairment and a lower quality of life than those
with less-frequent migraine.4 Expert opinion has
been that patients with chronic migraine should
receive preventive treatment2,5,6; however, these
treatments may be underused, not adhered to, associated with side effects, or ineffective.7,8
Fremanezumab (TEV-48125) is a humanized
IgG2a monoclonal antibody that selectively and
potently binds to calcitonin gene–related peptide
(CGRP),9,10 a 37–amino acid neuropeptide involved
in central and peripheral pathophysiological events
of migraine.11-13 Fremanezumab targets both α and
β isoforms of the CGRP ligand (not the receptor), has flexible dosing, and is administered by
means of subcutaneous injection.9,10 In a phase 2
trial involving patients with chronic migraine, the
numbers of migraine days and headache days
were significantly lower with fremanezumab than
with placebo, and no serious treatment-related
adverse events occurred.14 We conducted a 16week, double-blind, randomized, placebo-controlled, phase 3 trial with a 12-week active-intervention phase to evaluate the efficacy, safety,
and side-effect profile of two subcutaneous dose
regimens of fremanezumab for the preventive
treatment of chronic migraine.

Me thods
Trial Oversight

The protocol, available with the full text of this
article at NEJM.org, was approved by relevant ethics committees and institutional review boards.
The authors vouch for the conduct of the trial,
adherence to the protocol, and the accuracy and
completeness of the data and analyses and the
reporting of adverse events. The trial complied
with the International Conference on Harmonisation Guidelines for Good Clinical Practice, the
principles of the Declaration of Helsinki, and relevant national and local regulations. At the time of
2114
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screening, participants signed consent forms for
both this trial and a concurrent trial of frema
nezumab for episodic migraine (ClinicalTrials.gov
number, NCT02629861). The trial sponsor, Teva
Pharmaceuticals, provided the trial medication,
performed the data analysis, and funded the trial.
Assistance with manuscript preparation was provided by a medical writer funded by the sponsor.
Trial Participants

Patients were recruited at 132 sites in nine countries from March 2016 through January 2017.
These sites were clinics caring for persons with
headaches, and potential participants were identified from their databases. Key inclusion criteria
were an age of 18 to 70 years, a history of migraine
(according to the criteria of the International Classification of Headache Disorders, 3rd edition
[beta version], or ICHD-3 beta) for at least 12
months, and the fulfillment of the criteria for
chronic migraine during the 28-day preintervention period (headache of any duration or severity
on ≥15 days and headache meeting ICHD-3 beta
criteria for migraine on ≥8 days). The protocol
allowed inclusion of up to 30% of patients using
a stable dose of one migraine-preventive medication (hereafter referred to as preventive medication) for at least 2 months before the beginning
of the preintervention period to continue these
medications.
Key exclusion criteria were the use of onabotulinumtoxinA during the 4 months before
screening; the use of interventions or devices for
migraine, such as nerve blocks and transcranial
magnetic stimulation, during the 2 months before screening; the use of opioid or barbiturate
medications on more than 4 days during the preintervention period; and a lack of efficacy, after an
adequate therapeutic trial, of at least two of four
clusters of preventive medications, the details of
which are provided in the protocol.
Trial Design

This randomized, double-blind, placebo-controlled, parallel-group trial consisted of a screening visit, a 28-day preintervention period, and a
12-week intervention period, with a final evaluation at week 12. On the basis of the screening
visit and information collected in a daily diary
during the preintervention period, patients were
enrolled in the appropriate trial or were excluded
if they were not eligible for either trial.
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of headache days per month, and the mean change
from baseline in the average number of days per
month in which acute headache medication was
used during the 12-week period after the first
dose. A migraine day was defined as a calendar
day in which headache pain lasted at least 4 consecutive hours and met criteria for migraine (with
or without aura) or probable migraine (subtype in
which only one migraine criterion is absent), or
a day in which acute migraine–specific medication
(triptans or ergots) was used to treat a headache of
any duration. Other secondary end points included
the mean change from baseline in the number of
headache days during the 4-week period after
the first dose in all the patients and during the
12-week period after the first dose in patients
not receiving concomitant preventive medication, as well as the mean change in the score on
the six-item Headache Impact Test (HIT-6; scores
range from 36 to 78, with higher scores indicating a greater degree of headache-related disability)15 from baseline (day 0) to 4 weeks after administration of the last dose of the trial regimen.
Safety and side-effect profiles were evaluated
according to reported adverse events, vital signs
(systolic and diastolic blood pressure, pulse, body
temperature, and respiratory rate), physical examination, 12-lead electrocardiography, clinical
laboratory tests (serum chemical, hematologic,
coagulation, and urinalysis tests), systematic assessments of local injection-site reactions (erythema, induration, ecchymosis, and pain, all evaluated both immediately and 1 hour after dose
administration), concomitant medication use, and
suicidal ideation and behavior as assessed by
means of scores on the electronic Columbia–Suicide Severity Rating Scale. Serum levels of antiTrial End Points
drug antibodies were assessed with the use of a
The primary end point was the mean change in validated method.
the average number of headache days (days in
which headache pain lasted ≥4 consecutive hours Statistical Analysis
and had a peak severity of at least a moderate Estimations based on the phase 2b trial of
level or days in which acute migraine–specific fremanezumab in chronic migraine14 predicted
medication [triptans or ergots] was used to treat that a sample of 867 patients who had completed
a headache of any severity or duration) per month, the trial and could be evaluated would provide
comparing the baseline 28-day preintervention 90% power to detect a mean (±SD) difference of
period with the 12-week period after the first dose 1.7±6.3 in the average number of headache days
of the trial regimen.
per month between the fremanezumab-monthly
Secondary end points were the mean change group and the placebo group at a two-sided alfrom baseline in the average number of migraine pha level of 0.05. With an anticipated rate of
days per month, the percentage of patients with discontinuation of 15%, 1020 participants were
a reduction of at least 50% in the average number planned for randomization in this trial. Efficacy
Eligible patients were randomly assigned in a
1:1:1 ratio to receive fremanezumab quarterly,
fremanezumab monthly, or placebo. All the patients received three abdominal subcutaneous
injections at baseline and one injection at weeks
4 and 8. In the fremanezumab-quarterly group,
patients received a single dose of 675 mg of
fremanezumab at baseline (three injections of
225 mg per 1.5 ml), followed at weeks 4 and 8 by
placebo (one 1.5-ml injection). In the fremanez
umab-monthly group, patients received 675 mg
of fremanezumab at baseline (as above) and
225 mg of fremanezumab at weeks 4 and 8 (one
injection of 225 mg per 1.5 ml). In the placebo
group, placebo was administered as three 1.5-ml
injections at baseline and one 1.5-ml injection at
weeks 4 and 8. Randomization was performed
by means of electronic interactive-response technology, with stratification according to sex, country, and baseline use of preventive medication (yes
or no). Patients, investigators, the sponsor, and
trial staff were unaware of the trial-group assignments.
Patients were seen at five scheduled visits for
protocol-specified evaluations: at screening, baseline, weeks 4 and 8, and week 12, or at the time
of early withdrawal from the trial. Patients who
withdrew prematurely had final protocol-specified evaluations performed as soon as possible
after withdrawal. Headache data (e.g., occurrence,
duration, and pain severity; occurrence of photophobia, phonophobia, nausea, or vomiting; and
any use of migraine medication) were captured
daily through an electronic headache-diary device
(ERT DIARYpro platform on the Bluebird Pidion
BM-170 device).
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analyses were conducted in the modified intention-to-treat population, which included all randomly assigned patients who received at least one
dose of a trial regimen and had at least 10 days of
postbaseline efficacy assessments regarding the
primary end point. Safety analyses included all
randomly assigned patients who received at least
one dose of a trial regimen.
The primary end point was analyzed with the
use of an analysis of covariance. Trial regimen,
sex, country, and baseline use of preventive medication (yes or no) were used as fixed effects, and
the baseline number of migraine days and of years
since the onset of migraines were covariates. We
calculated 95% confidence intervals for the leastsquares mean differences between each frema
nezumab group and the placebo group. The Wilcoxon rank-sum test was performed as the
primary analysis if there was deviation from the
normality assumption as assessed by means of
the Shapiro–Wilk test. For management of missing data in the primary analysis, the average
number of headache days per month during the
12-week period was prorated to a 28-day equivalent with the use of all postbaseline observations.
The same analyses were used for relevant secondary end points. For the percentage of patients
with a reduction of at least 50% in the average
number of headache days per month, the Cochran–Mantel–Haenszel test was used, with baseline use of preventive medication (yes or no) as a
stratification variable.
To control the type I statistical error rate at
0.05, a hierarchical testing procedure was applied,
with a prespecified sequence of comparisons beginning with the primary end point and proceeding to secondary end points in the order given in
the protocol. Each comparison was performed
only if the preceding comparison had a two-sided
P value of 0.05 or less. Results are presented in
the sequence in which end points were evaluated.

R e sult s
Patients

A total of 1130 patients were randomly assigned
to one of the three trial regimens: 376 to frema
nezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo (Fig. S1 in the Supplementary Appendix, available at NEJM.org). Baseline
demographic and clinical characteristics were
similar among the three groups (Table 1). The
2116
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mean number of baseline headache days (as defined above) per month was 13.2 in the fremanezu
mab-quarterly group, 12.8 in the fremanezumabmonthly group, and 13.3 in the placebo group.
Of the randomly assigned patients, 1034 completed the trial: 349 (93%) in the fremanezumabquarterly group, 343 (91%) in the fremanezu
mab-monthly group, and 342 (91%) in the placebo
group (Fig. S1 in the Supplementary Appendix).
Efficacy

With respect to the primary end point, the mean
(±SE) number of headache days per month was
reduced by 4.3±0.3 days in the fremanezumabquarterly group, 4.6±0.3 days in the fremanez
umab-monthly group, and 2.5±0.3 days in the
placebo group (P<0.001 for both comparisons
with placebo) (Table 2 and Fig. 1A). For the 12
weeks of the intervention period, patients receiving placebo had an average of 10.4±6.4 headache
days, as compared with 8.5±6.3 days for those
receiving fremanezumab quarterly and 8.0±6.3
days for those receiving fremanezumab monthly.
There was a larger reduction in the average
number of migraine days per month with frema
nezumab quarterly (by 4.9±0.4 days) and frema
nezumab monthly (by 5.0±0.4 days) than with
placebo (by 3.2±0.4 days) (P<0.001 for both comparisons with placebo) (Table 2 and Fig. 1B).
Significantly more patients who received frema
nezumab had a reduction of at least 50% in the
average number of headache days per month
(quarterly regimen, 38%; monthly regimen, 41%)
than did patients who received placebo (18%)
(P<0.001 for both comparisons with placebo) (Table 2). There was a larger reduction in the average number of days per month in which acute
headache medication was used in the fremanez
umab groups (by 3.7±0.3 days with the quarterly
regimen and by 4.2±0.3 days with the monthly
regimen) than in the placebo group (by 1.9±0.3
days) (P<0.001 for both comparisons with placebo) (Table 2).
Treatment effects were observed in the average number of headache days per month during
the 4-week period after the first dose for all the
patients and during the 12-week period after the
first dose in the subgroup of patients not receiving concomitant preventive medication (P<0.001
for all comparisons with placebo) (Table 2). The
degree of headache-related disability decreased
between baseline and the 4-week period after
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Table 1. Baseline Characteristics of the Patients in the Intention-to-Treat Population, According to Trial Group.*
Fremanezumab
Quarterly
(N = 376)

Fremanezumab
Monthly
(N = 379)

Placebo
(N = 375)

Age — yr

42.0±12.4

40.6±12.0

41.4±12.0

Body-mass index†

26.6±5.4

26.5±5.1

26.5±5.0

Female sex — no. (%)

331 (88)

330 (87)

330 (88)

19.7±12.8

20.1±12.0

19.9±12.9

77 (20)

85 (22)

77 (21)

Current use of acute headache medication — no. (%)

359 (95)

360 (95)

358 (95)

Previous use of topiramate — no. (%)

106 (28)

117 (31)

117 (31)

66 (18)

50 (13)

49 (13)

Headache days‡

13.2±5.5

12.8±5.8

13.3±5.8

Days with headache of any severity and duration

20.4±3.9

20.3±4.3

20.3±4.2

Migraine days§

16.2±4.9

16.0±5.2

16.4±5.2

Days of use of any acute headache medications

13.1±6.8

13.1±7.2

13.0±6.9

Days of use of migraine-specific acute headache medications

11.3±6.2

11.1±6.0

10.7±6.3

64.3±4.7

64.6±4.4

64.1±4.8

Characteristic

Disease history
Time since initial migraine diagnosis — yr
Current use of preventive medication — no. (%)

Previous use of onabotulinumtoxinA — no. (%)
Disease characteristics during 28-day preintervention period

HIT-6 score¶

*	Plus–minus values are means ±SD. The intention-to-treat population included all the patients who underwent randomization. Patients in the fremanezumab-quarterly group received 675 mg at baseline and placebo at weeks 4 and 8; those
in the fremanezumab-monthly group received 675 mg at baseline and 225 mg at weeks 4 and 8; and those in the placebo group received placebo at baseline and at weeks 4 and 8. There were no significant between-group differences at
baseline for any characteristic.
†	The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡	A headache day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and had a
peak severity of at least a moderate level, or a day in which acute migraine–specific medication (triptans or ergots) was
used to treat a headache of any severity or duration.
§	A migraine day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and met criteria for migraine (with or without aura) or probable migraine (subtype in which only one migraine criterion is absent), or
a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any duration.
¶	The six-item Headache Impact Test (HIT-6) questionnaire assesses headache-related disability over the preceding
4 weeks, with scores ranging from 36 to 78 and with higher scores reflecting greater disability.

the last dose, with significantly greater reductions
in HIT-6 scores with fremanezumab quarterly
(by 6.4±0.5 points) and fremanezumab monthly
(by 6.8±0.4 points) than with placebo (by 4.5±0.5
points) (P<0.001 for both comparisons with placebo) (Table 2).
Safety

Adverse events were reported for 64% of the patients receiving placebo, 70% of those receiving
fremanezumab quarterly (P = 0.06 vs. placebo), and
71% of those receiving fremanezumab monthly
(P = 0.03 vs. placebo) (Table 3). Events were mild
to moderate in severity in 95 to 96% of the patients
in the three groups. A total of 20 patients disconn engl j med 377;22

tinued the trial owing to adverse events, including
1% in the fremanezumab-quarterly group, 2% in
the fremanezumab-monthly group, and 2% in the
placebo group.
Injection-site reactions were reported in 40%
of the patients receiving placebo, 47% of those receiving fremanezumab quarterly (P = 0.08 vs. placebo), and 47% of those receiving fremanezumab
monthly (P = 0.03 vs. placebo); the severity of injection-site reactions did not differ significantly
among the trial groups. The most common adverse
event was injection-site pain, which occurred in
30% of the patients in the fremanezumab-quarterly group, 26% of those in the fremanezumabmonthly group, and 28% of those in the placebo
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Table 2. Primary and Secondary End Points in the Modified Intention-to-Treat Population.*
Fremanezumab
Quarterly
(N = 375)†

Fremanezumab
Monthly
(N = 375)†

Placebo
(N = 371)

8.5±6.3

8.0±6.3

10.4±6.4

Least-squares mean change from baseline during 12-wk period after first dose

–4.3±0.3

–4.6±0.3

–2.5±0.3

Difference vs. placebo

–1.8±0.3

–2.1±0.3

—

Least-squares mean change from baseline during 12-wk period after first dose

–4.9±0.4

–5.0±0.4

–3.2±0.4

Difference vs. placebo

–1.7±0.4

–1.8±0.4

—

141 (38)

153 (41)

67 (18)

Least-squares mean change from baseline during 12-wk period after first dose

–3.7±0.3

–4.2±0.3

–1.9±0.3

Difference vs. placebo

–1.8±0.3

–2.3±0.3

—

Least-squares mean change from baseline during 4-wk period after first dose

–4.4±0.3

–4.5±0.3

–2.1±0.3

Difference vs. placebo

–2.3±0.4

–2.4±0.4

—

Patients evaluated — no. (%)

298 (79)

290 (77)

294 (79)

Least-squares mean change from baseline during 12-wk period after first dose

–4.6±0.3

–4.8±0.3

–2.6±0.3

Difference vs. placebo

–1.9±0.4

–2.2±0.4

—

Least-squares mean change from baseline during 4-wk period after last dose‡

–6.4±0.5

–6.8±0.4

–4.5±0.5

Difference vs. placebo

–1.9±0.5

–2.4±0.5

—

End Point
Primary end point
Average no. of headache days per month
Mean value during 12-wk period after first dose

Secondary end points
Average no. of migraine days per month

≥50% Reduction in average no. of headache days per month — no. of patients (%)
Average no. of days of use of any acute headache medication per month

Average no. of headache days per month

Average no. of headache days per month in patients not receiving concomitant
preventive medications

HIT-6 score

*	Plus–minus values are least-squares means ±SE. Efficacy analyses were conducted in the modified intention-to-treat population, which included all randomly assigned patients who received at least one dose of a trial regimen and had at least 10 days of postbaseline efficacy assessments regarding the primary end point. To control the type I statistical error rate at 0.05, a preplanned hierarchical testing procedure
was applied; end points are presented in the sequence in which they were evaluated. Baseline refers to the 28-day preintervention period unless otherwise indicated.
†	P<0.001 for all differences versus placebo, and for the comparison with placebo with respect to the percentage of patients with a reduction
of at least 50% in the average number of headache days per month.
‡	Shown is the change from baseline (day 0) during the 4-week period after administration of the last (third) dose of the trial regimen.

group (Table 3). Injection-site induration and
erythema were more frequent with fremanezumab
than with placebo.
Serious adverse events occurred in 2% of the
patients given placebo, 1% of those given frema
nezumab monthly, and less than 1% of those given
fremanezumab quarterly (Table 3, and Table S2
in the Supplementary Appendix). No serious adverse event occurred in more than one patient.
One death occurred in the fremanezumab-quarterly group, 69 days after the patient received
fremanezumab at a dose of 675 mg, which was
2118
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determined on the basis of an autopsy to be due
to chronic obstructive pulmonary disease (COPD).
Except for the event of fatal COPD, all serious
adverse events resolved or were resolving by the
end of the trial. One serious adverse event led to
discontinuation of the trial; an event of suicidal
ideation (assessed by the investigator as being
moderate in severity and unrelated to the trial
regimen) was reported in a patient in the frema
nezumab-monthly group who had a history of
depression.
Events of possible trial-agent–induced liver in-
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Discussion
This phase 3 trial of fremanezumab in chronic
migraine showed a significant benefit of frema
nezumab over placebo with respect to the avern engl j med 377;22

A Headache Days
Least-Squares Mean Change from Baseline
in Average No. of Headache Days per Month

0

Fremanezumab quarterly (N=375)
Fremanezumab monthly (N=375)
Placebo (N=371)

–1
–2
–3
–4

†
†

–5

†

†

†

†

–6
–7
–8

Difference between fremanezumab quarterly and
placebo during 12-wk period, –1.8±0.3 days/mo (P<0.001)

–9

Difference between fremanezumab monthly and
placebo during 12-wk period, –2.1±0.3 days/mo (P<0.001)

–10

Baseline

4

8

12

Week after First Injection

B Migraine Days
0

Least-Squares Mean Change from Baseline
in Average No. of Headache Days per Month

jury (aspartate aminotransferase or alanine transaminase level ≥3 times the upper limit of the
normal range, total bilirubin level ≥2 times the
upper limit of the normal range, or international
normalized ratio >1.5) occurred in three patients
in the placebo group (<1%) and five patients in
each of the fremanezumab groups (1%) (P = 0.73
for each fremanezumab group vs. placebo and
P = 0.56 for the combined fremanezumab groups
vs. placebo) (Table 3). Eight patients (1%) who
received fremanezumab had liver enzyme levels
that were higher than normal but less than 3 to
5 times the upper limit of the normal range,
which were transient and reverted to normal
levels without discontinuation of the trial regimen. None of these events were considered by
investigators as being serious, and none led to
discontinuation of the trial. All the patients with
liver enzyme levels that were higher than normal
but less than 3 to 5 times the upper limit of the
normal range (in the placebo or fremanezumab
groups) had used nonsteroidal antiinflammatory drugs or acetaminophen frequently or had
used antidepressants daily. Two patients receiving fremanezumab (<1%) had an aspartate aminotransferase or alanine transaminase level more
than 5 times the upper limit of the normal range.
One of these patients had an alanine transaminase level 6.5 times the upper limit of the normal
range at a single visit, and the level normalized
without intervention while the patient was receiving the trial regimen. The other patient had
an alanine transaminase level 6 times the upper
limit of the normal range at baseline as well as
an elevated level at visit 4, while being treated for
an upper respiratory tract infection with medications containing ethanol. Values normalized after discontinuation of the ethanol-containing drug,
while the patient was still receiving the trial
regimen.
No participants had anaphylaxis or a severe
hypersensitivity reaction. Antidrug antibodies developed in two patients who received fremanez
umab quarterly. No clinically significant changes
in vital signs, physical-examination findings, or
electrocardiographic results occurred in any of
the trial groups.

Fremanezumab quarterly (N=375)
Fremanezumab monthly (N=375)
Placebo (N=371)

–1
–2
–3
–4
†

–5

†

†
†

–6

*
†

–7
–8

Difference between fremanezumab quarterly and
placebo during 12-wk period, –1.7±0.4 days/mo (P<0.001)

–9

Difference between fremanezumab monthly and
placebo during 12-wk period, –1.8±0.4 days/mo (P<0.001)

–10

Baseline

4

8

12

Week after First Injection

Figure 1. Primary and Secondary End Points.
Panel A shows the change from baseline in the average number of headache days per month during the 12-week period after the first dose of the
trial regimen (primary end point), and Panel B shows the change from
baseline in the average number of migraine days per month during the
12-week period after the first dose of the trial regimen (secondary end
point). A headache day was defined as a calendar day in which headache
pain lasted at least 4 consecutive hours and had a peak severity of at least
a moderate level, or a day in which acute migraine–specific medication
(triptans or ergots) was used to treat a headache of any severity or duration. A migraine day was defined as a calendar day in which headache pain
lasted at least 4 consecutive hours and met criteria for migraine (with or
without aura) or probable migraine (subtype in which only one migraine
criterion is absent), or a day in which acute migraine–specific medication
(triptans or ergots) was used to treat a headache of any duration. An asterisk denotes P = 0.006 for the comparison with placebo, and a dagger P<0.001
for the comparison with placebo. I bars indicate standard errors. Changes
from baseline to weeks 4, 8, and 12 are part of exploratory analyses.
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Table 3. Adverse Events in the Safety Population, According to Trial Group.*
Fremanezumab
Quarterly
(N = 376)

Event

Fremanezumab
Monthly
(N = 379)

Placebo
(N = 375)

number of patients (percent)
At least one adverse event

265 (70)

270 (71)

240 (64)

At least one adverse event related to the trial regimen

186 (49)

194 (51)

159 (42)

At least one serious adverse event

3 (<1)

5 (1)

6 (2)

Any adverse event leading to discontinuation of the trial†

5 (1)

7 (2)

8 (2)

Death‡

1 (<1)

0

0

Adverse events reported in >2% of patients in any group
Injection-site reactions
Pain

114 (30)

99 (26)

104 (28)

Induration

74 (20)

90 (24)

68 (18)

Erythema

80 (21)

75 (20)

60 (16)

7 (2)

8 (2)

10 (3)

Nasopharyngitis

19 (5)

15 (4)

20 (5)

Upper respiratory tract infection

18 (5)

16 (4)

15 (4)

Sinusitis

10 (3)

4 (1)

10 (3)

Dizziness

9 (2)

11 (3)

5 (1)

Nausea

4 (1)

6 (2)

11 (3)

Hemorrhage
Infections

Possible trial-agent–induced liver injury§

5 (1)

5 (1)

3 (<1)

Alanine aminotransferase ≥3× ULN

2 (<1)

3 (<1)

1 (<1)¶

Aspartate aminotransferase ≥3× ULN

3 (<1)

2 (<1)

Total bilirubin ≥2× ULN

2 (<1)

0

0

0

1 (<1)

International normalized ratio >1.5

0

0

*	Shown are data collected during the double-blind, placebo-controlled intervention period. The safety population included all the patients who underwent randomization and received at least one dose of a trial regimen. ULN denotes upper
limit of the normal range.
† One serious adverse event led to discontinuation of the trial; an event of suicidal ideation (assessed by the investigator
as being moderate in severity and unrelated to the trial regimen) was reported in a patient in the fremanezumab-monthly
group who had a history of depression.
‡	One death occurred in the fremanezumab-quarterly group as a result of chronic obstructive pulmonary disease; this
was determined by the investigator and sponsor to be unrelated to the trial regimen.
§	Patients could have more than one type of possible trial-agent–induced liver injury.
¶	An event was reported in one additional patient but was inadvertently omitted as an adverse event of special interest.

age number of headache days per month (difference vs. placebo, approximately −2 days per month),
the number of migraine days, and headache-related disability. Treatment effects were seen within
4 weeks after the initial dose.
These results are consistent with those of the
phase 2b trial of fremanezumab in chronic migraine,14,16 with early onset of efficacy and similar
treatment effects for both the monthly and quarterly regimens, although no direct comparison
2120
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between dose regimens was made. The primary
end point as defined in this trial adhered to International Headache Society recommendations
and is identical to that used in the pivotal trials
of onabotulinumtoxinA,17-19 a preventive therapy
approved by the Food and Drug Administration
for chronic migraine. Fremanezumab probably
exerts clinical effects through inhibition of the
migraine-specific target CGRP and, as a monoclonal antibody, has pharmacologic properties
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that are distinct from those of other preventive
treatments, including a half-life that supports a
long duration of action and long intervals between doses.20
Discontinuation of the trial due to adverse
events was infrequent, a finding consistent with
those of previous trials.14 Fremanezumab was
associated with a higher incidence of injection-site
reactions than placebo, but the severity of such
reactions did not differ significantly among the
trial groups. Because systematic assessment of
injection sites was required for 1 hour after dose
administration, the rates of the specific injection-site reactions in this trial may have been
higher than those previously reported. Frema
nezumab, a monoclonal antibody, is not metabolized in the liver and is eliminated through catabolism to smaller peptides or amino acids.20 Mild
transient elevations in liver enzyme levels occurred,
and the levels reverted to normal without discontinuation of the trial regimen. All the patients who
had these elevations used concomitant medications with a potential to cause increases in liver
enzyme levels. Endogenous CGRP is a vasodilator,
but there were no hemodynamic changes with
fremanezumab. There was one death from chronic pulmonary disease and one case of suicidal
ideation in patients receiving the active drug.
The latter occurred in a patient with a history of
depression and was judged not to be related to
the trial drug.
The current trial was conducted in parallel
with a trial evaluating fremanezumab in episodic
migraine, allowing persons who were ineligible
for one trial to be considered for the other. Although the current trial included patients with a
long history of disease and those who had previously not had a response to or were currently
taking preventive medications, it did not include
patients with more refractory disease — those
who had not had a response to at least two clusters of preventive medications or who had continuous headache. As in other clinical trials of
migraine treatment, eligibility was still restrictReferences
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